The first week of May included several notable announcements about efforts to create a coronavirus vaccine. In the U.S., the Massachusetts-based biotech company Moderna announced Thursday that their coronavirus vaccine candidate received approval from the Food and Drug Administration to proceed with a second round of clinical trials. And scientists at the pharmaceutical company Pfizer are working on a new vaccine that they say could be available by September.
In the U.K., scientists at the University of Oxford made waves recently when researchers there said that they may be able to evaluate the effectiveness of their candidate this summer, and the vaccine could subsequently be available by September.
Here's a roundup of the most notable vaccine news of the week.
You do not have permission to view the full content of this post. Log in or register now.
Moderna is moving forward with a second phase of clinical trials after receiving clearance from the FDA.
Like Pfizer, Moderna’s vaccine candidate is based on specially designed messenger RNA. The company’s first phase of human clinical trials, involving more than 100 healthy volunteers, was conducted in March.
If the second round of trials is successful, Moderna said it anticipates beginning the third phase of clinical trials, which is designed to demonstrate that the vaccine is effective in different populations, in early summer.
By Denise Chow, NBCNews, Staff Writer
May 29, 2020, 1:07 AM PST
In the U.K., scientists at the University of Oxford made waves recently when researchers there said that they may be able to evaluate the effectiveness of their candidate this summer, and the vaccine could subsequently be available by September.
Here's a roundup of the most notable vaccine news of the week.
You do not have permission to view the full content of this post. Log in or register now.
Moderna is moving forward with a second phase of clinical trials after receiving clearance from the FDA.
Like Pfizer, Moderna’s vaccine candidate is based on specially designed messenger RNA. The company’s first phase of human clinical trials, involving more than 100 healthy volunteers, was conducted in March.
If the second round of trials is successful, Moderna said it anticipates beginning the third phase of clinical trials, which is designed to demonstrate that the vaccine is effective in different populations, in early summer.
By Denise Chow, NBCNews, Staff Writer
May 29, 2020, 1:07 AM PST